Aim Immunotech Inc (AIM) - News Archive

In the evolving landscape of oncology and infectious disease management, AIM ImmunoTech Inc. (NYSE American: AIM) has recently captured attention by detailing significant findings from completed clinical trials. The com...

Ampligen: A Promising Player in the Fight Against Cancer and Viral Infections AIM ImmunoTech Inc. continues to push the frontiers in the field of immunotherapy, with a series of compelling announcements highlighting the...

AIM ImmunoTech Inc.: Navigating Financial Turbulence Amidst Strategic Ambitions in the Post-COVID Healthcare LandscapeIn a recent press release dated February 11, 2025, AIM ImmunoTech Inc. (NYSE American: AIM) made a cr...

AIM ImmunoTech s Tumultuous Road: High Hopes vs. Historic Losses in the Post-COVID Healthcare LandscapeAIM ImmunoTech Inc. a biotechnology company known for its work on the immunotherapy drug Ampligen (rintatolimod), ha...

AIM ImmunoTech s Compliance Strategy Amidst Market Struggles: Navigating Noncompliance and Patent Expansion in Post-COVID TreatmentIn a recent press release, AIM ImmunoTech Inc. announced its receipt of a notification f...

AIM ImmunoTech Inc. has recently made strides in expanding its patent portfolio, particularly through the addition of a significant new patent granted by the Netherlands Patent Office. This development marks a crucial s...

AIM ImmunoTech (NYSE American: AIM), a biotechnology company primarily focused on advancing immune-based therapies for patients with severe diseases, has recently made significant strides in enhancing its communication...

In a significant advancement within the realm of oncology, AIM ImmunoTech Inc. (NYSE American: AIM) has announced that pivotal data concerning Ampligen (rintatolimod) an innovative therapeutic agent have been published...

On September 30, 2024, AIM ImmunoTech Inc. (NYSE American: AIM) announced a significant financial move, entering into a securities purchase agreement with a single institutional investor for a registered direct offering...

The landscape of cancer treatment continually evolves as researchers and companies strive for improvements in efficacy and patient outcomes. Recently, AIM ImmunoTech announced encouraging preliminary data from its Phase...

Exploring the Potential of Ampligen in Alleviating Post-COVID Fatigue: AIM ImmunoTech s Promising Developments AIM ImmunoTech Inc. has recently completed a comprehensive analysis of clinical patient data related to its...

Pioneering Research: AIM ImmunoTech Reveals Promising Outcomes in Ampligen s Role in Pancreatic Cancer TreatmentAIM ImmunoTech has recently garnered significant attention in both the medical community and investment cir...

In a significant development for the field of oncology, AIM ImmunoTech Inc. (NYSE American: AIM) has announced the release of the latest segment of its CEO Corner, where the company’s Chief Executive Officer, Thomas Equ...

In a groundbreaking development, AIM ImmunoTech Inc. (AIM) has recently published new preclinical data that highlights the potential of their drug Ampligen as a crucial component in combination therapy for the treatment...

AIM ImmunoTech s Strategic Funding Move Raises Questions Amidst Challenging Financial PerformanceIn a recent announcement, AIM ImmunoTech Inc. revealed the pricing details of its registered direct offering to raise $2.0...

AIM ImmunoTech, a specialized biopharmaceutical company focused on research and development, recently announced that the first dose level of their Phase 1b/2 study involving a combination therapy of Ampligen and Imfinzi...

AIM ImmunoTech Inc. Highlights Unmet Need and Potential Treatment for Locally Advanced Pancreatic AdenocarcinomaOCALA, Fla., April 18, 2024 - AIM ImmunoTech Inc. (NYSE American: AIM) is a biopharmaceutical company dedic...

Pancreatic cancer remains one of the most challenging and deadly forms of cancer, with limited treatment options available. However, recent groundbreaking research has shed light on the potential benefits of utilizing A...

In a recent announcement, AIM ImmunoTech Inc. (NYSE American: AIM) disclosed the release of the latest CEO Corner segment, shedding light on the company s clinical development program and its focus on addressing the unm...

Introducing AIM ImmunoTech s CEO Corner: Providing Enhanced Insight and Perspective on Corporate Developments and Pipeline ProgressAIM ImmunoTech, a leading biopharmaceutical company focused on the development of immune...